Welcome to our dedicated page for Sarepta Therapeutics news (Ticker: SRPT), a resource for investors and traders seeking the latest updates and insights on Sarepta Therapeutics stock.
Sarepta Therapeutics, Inc. develops and commercializes precision genetic medicines for rare diseases, with a central focus on Duchenne muscular dystrophy and other neuromuscular conditions. Company news commonly covers product revenue and commercialization trends for ELEVIDYS and PMO therapies, including AMONDYS 45, VYONDYS 53 and EXONDYS 51.
Updates also address FDA interactions for Duchenne therapies, clinical and biomarker data from the siRNA pipeline, and programs such as SRP-1001 for FSHD1 and SRP-1003 for DM1. Other recurring announcements include quarterly financial results, Nasdaq inducement equity grants, and patient-community initiatives tied to Duchenne muscular dystrophy.
Sarepta Therapeutics (NASDAQ:SRPT) reported Q1 2026 results with total revenues of $730.8 million and net product revenues of $330.5 million (ELEVIDYS $102.0M; PMO $228.6M). GAAP operating income was $358.4 million. Cash and investments totaled $748.3 million as of March 31, 2026. Clinical and regulatory progress included early Phase 1/2 siRNA data for SRP-1001 and SRP-1003, ENDEAVOR Cohort 8 dosing underway, and sNDA submissions for AMONDYS 45 and VYONDYS 53.
Company reiterated FY2026 revenue guidance of $1.2–$1.4 billion and combined non-GAAP R&D and SG&A guidance of $800–$900 million.
Sarepta Therapeutics (NASDAQ:SRPT) will report first quarter 2026 financial results after the Nasdaq close on Wednesday, May 6, 2026. A conference call and live webcast will follow at 4:30 p.m. ET, with a replay archived for one year.
Phone participants must register online to receive dial-in details and a personal PIN. Investors are encouraged to consult the company's investor relations site for related filings and materials.
Sarepta Therapeutics (NASDAQ:SRPT) granted inducement equity awards on March 31, 2026 to 24 employees hired in Q1 2026 under the company’s 2024 Employment Commencement Incentive Plan. The awards total 113,855 restricted stock units (RSUs) and vest 25% annually over four years, subject to continued employment. Awards were approved pursuant to Nasdaq Listing Rule 5635(c)(4). No stock options were granted.
Sarepta (NASDAQ:SRPT) reported first clinical data from Phase 1/2 studies of two αvβ6 integrin-targeted siRNA candidates, SRP-1001 (FSHD1) and SRP-1003 (DM1).
Early results show dose-dependent muscle and plasma exposures, single-dose target knockdown, and favorable tolerability with no dose-limiting toxicities reported to date. An investor webcast is scheduled March 25, 2026.
Sarepta (NASDAQ:SRPT) will present early clinical results from Phase 1/2 ascending‑dose studies of SRP‑1001 (FSHD1) and SRP‑1003 (DM1) on March 25, 2026 at 8:30 AM ET via live webcast and conference call.
Replay will be archived on the investor relations site for one year; phone participants must register to receive dial‑in and PIN details.
Sarepta (NASDAQ:SRPT) will submit supplemental NDAs by the end of April 2026 seeking conversion of AMONDYS 45 and VYONDYS 53 accelerated approvals to traditional approvals.
ESSENCE topline showed non‑significant primary results (LSM difference 0.06 steps/sec, P=0.309); an updated COVID‑adjusted analysis reached P=0.050. No new safety signals; company will include ESSENCE and real‑world evidence in the sNDAs.
Sarepta (NASDAQ:SRPT) announced screening and enrollment are underway in ENDEAVOR Cohort 8 to test a prophylactic sirolimus-enhanced immunosuppression regimen alongside ELEVIDYS in non-ambulatory Duchenne patients. Approximately 25 participants will receive 14 days of peri-infusion sirolimus plus continued dosing for 12 weeks. Primary endpoints are incidence of acute liver injury (ALI) and ELEVIDYS-dystrophin expression at 12 weeks. ENDEAVOR has enrolled 55 participants across seven cohorts; ELEVIDYS has been administered to over 1,200 patients globally. The cohort aims to assess whether sirolimus mitigates ALI risk in older, non-ambulatory patients.
Sarepta Therapeutics (NASDAQ:SRPT) opened applications for Route 79, The Duchenne Scholarship Program for the 2026-2027 academic year. Scholarships of up to $5,000 will be awarded to up to 20 individuals with Duchenne and up to 5 siblings.
Applications are accepted through May 15, 2026; recipients will be notified before July 31, 2026 and awards distributed to schools for fall 2026 enrollment.
Sarepta Therapeutics (NASDAQ:SRPT) will present new long-term efficacy, safety and caregiver-reported data at the Muscular Dystrophy Association Clinical & Scientific Conference, March 8–11, 2026 in Orlando.
Key items include a late-breaking oral on delandistrogene moxeparvovec (EMBARK) functional outcomes up to 3 years versus a matched external control, a pooled safety analysis with up to 7.5 years follow-up, Phase 3 ESSENCE topline results for golodirsen and casimersen, caregiver impressions through 2 years, and multiple real-world and pharmacokinetic posters.
Sarepta Therapeutics (NASDAQ:SRPT) reported Q4 2025 and full‑year results on Feb 25, 2026: FY2025 revenue $2,198.2M (+16% YoY), Q4 revenue $442.9M, and net product revenue for FY2025 of $1,864.3M (PMO $965.6M; ELEVIDYS $898.7M). GAAP net loss for FY2025 was $713.4M (GAAP diluted loss per share $7.13). Cash, cash equivalents and investments were $953.8M at 12/31/2025. Corporate actions included refinancing 2027 notes into 2030 notes, ELEVIDYS launch in Japan (eligible $40M milestone), positive 3‑year EMBARK data, and advancing multiple siRNA programs with a Huntington’s CTA approved to start in Q2 2026.